Cutaneous mucormycosis: report of five cases and review of the literature. | Canada Hyperbarics Skip to main content
Review Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2009

Cutaneous mucormycosis: report of five cases and review of the literature.

Arnáiz-García ME, Alonso-Peña D, González-Vela Mdel C, García-Palomo JD, Sanz-Giménez-Rico JR, Arnáiz-García AM — Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2009

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers reported five cases of cutaneous mucormycosis treated at their institution and reviewed existing literature on the condition.

What They Found

The study reported on five cases of cutaneous mucormycosis, highlighting its aggressive and potentially lethal nature, especially in immunocompromised patients. They found that early diagnosis through histopathology and culture, combined with standard treatment of antifungal therapies and surgical debridement, is crucial for patient survival.

What This Means for Canadian Patients

Canadian patients presenting with suspected cutaneous mucormycosis should receive prompt diagnostic evaluation, including tissue examination and culture, due to the infection's aggressive nature. Rapid initiation of combined antifungal therapy and surgical debridement is essential to improve outcomes and prevent potentially lethal complications.

Canadian Relevance

This study has no direct Canadian connection as it reports cases from a specific institution outside Canada.

Study Limitations

A key limitation is the small sample size of five cases, which restricts the generalizability of the findings beyond the specific patients reported.

Was this summary helpful?

Study Details

Study Type Review
Category Infection
Source Pubmed
PubMed ID 18684680
Year Published 2009
Journal Journal of plastic, reconstructive & aesthetic surgery : JPRAS
MeSH Terms Adult; Aged; Antifungal Agents; Combined Modality Therapy; Debridement; Dermatomycoses; Follow-Up Studies; Humans; Hyperbaric Oxygenation; Immunocompromised Host; Immunohistochemistry; Male; Mucormycosis; Risk Assessment; Sampling Studies

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.